Zheng Feng
Director & Head of Clinical Genomics, Clinical Biomarker Technologies EMD Serono
Seminars
Wednesday 24th September 2025
Panel Discussion: Improving Patient Monitoring through Innovations in Liquid Biopsy Analysis
3:30 pm
- What are the recent innovations in liquid biopsy derived markers and how to integrate these into clinical trial designs?
- How can we build successful liquid biopsy collaborations to pioneer future trial design?
Wednesday 24th September 2025
Clinical Applications of Liquid Biopsy in Advancing Precision Oncology-Driven Drug Development: Current Trends & Future Directions
2:40 pm
- Overview of ctDNA applications in clinical drug development with a focus on adjuvant settings and mechanism of tumor shedding
- Developing a fit-for-purpose liquid biopsy strategy
- Navigating future directions by balancing novel technologies with clinical application realities
- Looking ahead: AI and GPT-current status and future implications
Thursday 25th September 2025
Panel Discussion: Paving Towards Strategic Drug-Diagnostic Market Entry Across APAC – From Trial Design to Commercial Success
9:00 am
- Which potential challenges in trial design are we aware of?
- Which CDx strategy and testing models are optimal for maximizing market patient access across APAC and how does this differ per region?
- What are the CDx policies and regulations across APAC, and how can we address critical bottlenecks regarding regulatory adherence and commercialization?
- What precision medicine marker developments are currently underway which might change the future testing paradigm? How might this inform vendor selection?
